A lawsuit filed Monday alleges the three companies that make insulin have been part of an “
organised scheme to drive up prices at the expense of patients who need insulin drugs to live.”
Insulin is a hormone that helps people absorb and process the sugar in food. Roughly 1.25 million people in the US who have Type 1 diabetes need to inject insulin to live, as do many people with Type 2 diabetes, the more common form.
The complaint filed in the US District Court of Massachusetts details examples of patients who pay $900 a month for the drug, as well as people who induced diabetic ketoacidosis — a potentially fatal condition in which the body builds up too much of a certain blood acid because there isn’t enough insulin in the body — to have access to insulin samples in the emergency room.
The suit alleges that the drug companies — Novo Nordisk, Sanofi, and Lilly — violate the Racketeer Influenced and Corrupt Organisations Act.
“People living with diabetes are practically imprisoned under the price hikes and sadly are resorting to extreme measures to afford the medication they need to live,” Steve Berman, a managing partner at the legal firm representing the patients in the lawsuit. The lawsuit is seeking class action status.
The companies could not immediately be reached for comment.
In the past few years, the list price of insulin has increased routinely, often in lockstep with competitors. Here’s what the list prices for Humalog and Novolog, two short-acting insulins has been over the last 20 years.
However, the list price doesn’t tell the entire story. While drugmakers set their list prices, there are a number of middlemen who get a piece of a drug’s sale — in particular, pharmacy benefits managers, or companies that negotiate rebates from drug companies that get passed on to insurers, and ideally patients.
Drugmakers pay rebates out to pharmacy benefits managers and insurance companies, and those rebates are increasing in part just so the companies can ensure their drug is kept on the list of approved drugs for a certain treatment.
Once those rebates are factored in, drug companies get something called the net price, which can often tell a different story from the routine price increases. For example, Lilly told Business Insider that the net price for its insulin Humalog was down 24% in the third-quarter of 2016, from the third-quarter of 2015.
According to data from ZS Associates, a sales and marketing firm that works in the healthcare industry, the rebates paid out by the Novo, Lilly and Sanofi were higher in 2015 than they were in 2014. And across the industry, ZS data shows that rebates paid out to PBMs and insurers have gone up from about $40 billion four years ago to $100-$130 billion by 2016.
The three insulin-makers aren’t the only companies in the spotlight for drug price-fixing. In December, the Department of Justice accused two executives of fixing prices of a generic antibiotic and an anti-diabetic medication. And 20 state attorneys have sued generic drugmakers, alleging that they fixed-price and colluded regarding the same two drugs.
What drugmakers have done to counter pricing pressure
- Sanofi, which makes the long-acting insulin Lantus, hasn’t increased its list price since 2014.
- In December, Lilly came out with a discount of up to 40% for people with high-deductible insurance plans. The discounts come through an app called Blink Health, which lets users pre-pay for your prescriptions to lock in discounts. Lilly also released a cheaper long-acting insulin, called Basaglar, that comes at a discount to its competitors.
- Novo Nordisk committed to limiting all future drug list price increases from the company to single digit percentages.
NOW WATCH: Money & Markets videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.